Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer

NCT01815307 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

NETWORK

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: Gemcitabine
DRUG: S-1

Sponsor

Kansai Hepatobiliary Oncology Group